Rare Daily Staff
Imara, a company developing therapies targeting rare inherited genetic disorders of hemoglobin, has launched its Real Impact community support initiative to support nonprofit, community-based organizations serving patients and families impacted by sickle cell disease and beta-thalassemia.
Imara said it will fund between 15 and 20 grants in 2020 totaling up to $100,000 across three key areas: social health impact programs, COVID-19 relief programs, and organizational capacity enhancement programs. The grants, which will be up to $5,000 each, will be awarded to recipients in the United States.
“We know that the current COVID-19 pandemic places an additional burden on those who are affected by rare or chronic diseases,” said Rahul Ballal, president and CEO of Imara.
Applications will be accepted online from May 6 through 11:59 p.m. EST on June 3, 2020. Nonprofit organizations may apply for grants in up to two categories, and each submission requires a separate application.
A team of reviewers will evaluate the applications and determine the final grant recipients based on the clear identification of an unmet need, plan of execution, level of impact within the target community and measures of success. Recipients across the three grant programs will be announced and awarded in June 2020.
All applications must be submitted through the online process and include the required supporting materials. For additional information on the grants, eligibility criteria and instructions on how to apply, CBOs can refer to the application website: Imara’s Real Impact Awards.
Photo: Rahul Ballal, president and CEO of Imara
Stay Connected
Sign up for updates straight to your inbox.